Incyte

EMA: EC Decision: Label Extension / New Indication: Iclusig (ponatinib)

European Commission approved a label extension for Iclusig (ponatinib, Incyte) on May 13, 2026, expanding the indication in adult patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. This represents a label expansion for the already-approved oncology drug, adding refined indication language or new resistance patterns. Incyte maintains its position in the specialized tyrosine kinase inhibitor market for treatment-resistant blood cancers where therapeutic options remain limited.